Home > Children & Young People > Allergy >

Adrenaline Auto-Injectors (AAI)

Checked: 06-10-2020 by Vicky Ryan Next Review: 06-10-2021

Local guidelines

See the Bristol Royal Hospital for Children (BRHC) guidelines on Adrenaline Auto Injectors

The guidance includes types of AAI, Suggested algorithm for provision of an AAI, Risk assessment and Prescribing AAIs.

Number of devices required

The BRHC allergy team recommend that two AAIs should be prescribed if indicated by the risk assessment. In general it is expected that these AAIs should follow the child in all settings (along with other medications indicated in their allergy management plan such as antihistamines and salbutamol inhalers).

Families often request more AAIs for other childcare settings (e.g. nurseries) and schools. Prescriptions of additional AAIs are at the discretion of the patient’s GP. However, the allergy team recommends that:

• For infants and primary school aged children - no more than one further additional AAI in recognition of the changes to the Human Medicines Regulations on the 1st October 2017 that allows all schools to buy AAI devices without a prescription. (A total of three devices)

• Secondary school aged children should keep both their devices on their person at all times, including when they are in school. (A total of two devices)

If there is uncertainty about whether an AAI is required or how many AAIs to prescribe please contact the BRHC allergy team’s Advice and Guidance service via ERS

Patient Information Leaflet

Please see the attached BRHC Patient Information Leaflet for AAIs

Efforts are made to ensure the accuracy and agreement of these guidelines, including any content uploaded, referred to or linked to from the system. However, BNSSG ICB cannot guarantee this. This guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, in accordance with the mental capacity act, and informed by the summary of product characteristics of any drugs they are considering. Practitioners are required to perform their duties in accordance with the law and their regulators and nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.

Information provided through Remedy is continually updated so please be aware any printed copies may quickly become out of date.